Hangzhou Rongze Biotechnology Group Co., Ltd. is a national high-tech enterprise focusing on the development of products in the field of cell and gene therapy (CGT) with organoid regenerative medicine as the core. It has established several regenerative medicine and CGT drug research and development laboratories in Shanghai and Hangzhou, which follow GMP standards. Over the years, Rongze Group has successfully developed organoid models for diseases such as cardiomyopathy, various solid tumors, and diabetic foot, leveraging its advanced regenerative medicine platform. The group has also established a globally leading platform for the development of drugs using immune cells, stem cells, genes, and exosomes. With these technological advantages, the group has developed several key models and stem cell, immune cell, exosome, and AAV gene therapy drugs for major diseases such as cancer, liver cirrhosis, cartilage defects, and hereditary cardiomyopathy. These products not only have commercial value but also represent technological leadership. After years of deep cultivation in the field of cells and genes, Rongze Group has established an industrial layout and development model of "regenerative medicine basic platform + cell and gene drug research and development". Looking forward to the future, Rongze Group will continue to promote the development of Chinas regenerative medicine and innovative pharmaceuticals, effectively use the power of life science, and enhance human health and well-being.